Consistency, Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults greater than and equal to 50 Years of Age
Phase of Trial: Phase III
Latest Information Update: 30 May 2017
At a glance
- Drugs GSK 1437173A (Primary)
- Indications Herpes zoster
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline
- 16 Jun 2016 Status changed from active, no longer recruiting to completed.
- 13 Jun 2016 This trial is Completed in Belgium, according to the European Clinical Trials Database.
- 17 Jun 2015 Planned End Date changed from 1 Apr 2016 to 1 May 2016 as reported by ClinicalTrials.gov record.